Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy S Abramson

Showing results (1-10 of 198) with videos related to

Pageof 20
Sort By:
The Oncologist|April 15, 2006
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and managementJeremy S Abramson
Blood|December 15, 2022
Post-CAR relapse in DLBCL: a fork in the roadJeremy S Abramson
Cancer|July 10, 2019
Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?Jeremy S Abramson
Leukemia & Lymphoma|September 6, 2007
T-cell/histiocyte-rich B-cell lymphoma and the paradox of the host immune responseJeremy S Abramson
Leukemia & Lymphoma|October 26, 2016
Bone marrow biopsies for staging of diffuse large B-cell lymphoma: are we looking too closely?Jeremy S Abramson
Hematology/Oncology Clinics of North America|November 28, 2016
The Spectrum of Double Hit LymphomasJeremy S Abramson
Blood|January 28, 2017
Recurrent mutations and targeted therapy in FLJeremy S Abramson
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Transformative Clinical Trials in Non-Hodgkin and Hodgkin LymphomasJeremy S Abramson
Transfusion Medicine Reviews|November 4, 2019
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin LymphomaJeremy S Abramson
Transplantation and Cellular Therapy|October 6, 2022
Choosing a CAR for Relapsed/Refractory Large B-cell LymphomaJeremy S Abramson
Pageof 20

Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
The Oncologist|April 15, 2006
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and managementJeremy S Abramson
Blood|December 15, 2022
Post-CAR relapse in DLBCL: a fork in the roadJeremy S Abramson
Cancer|July 10, 2019
Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?Jeremy S Abramson
Leukemia & Lymphoma|September 6, 2007
T-cell/histiocyte-rich B-cell lymphoma and the paradox of the host immune responseJeremy S Abramson
Leukemia & Lymphoma|October 26, 2016
Bone marrow biopsies for staging of diffuse large B-cell lymphoma: are we looking too closely?Jeremy S Abramson
Hematology/Oncology Clinics of North America|November 28, 2016
The Spectrum of Double Hit LymphomasJeremy S Abramson
Blood|January 28, 2017
Recurrent mutations and targeted therapy in FLJeremy S Abramson
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Transformative Clinical Trials in Non-Hodgkin and Hodgkin LymphomasJeremy S Abramson
Transfusion Medicine Reviews|November 4, 2019
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin LymphomaJeremy S Abramson
Transplantation and Cellular Therapy|October 6, 2022
Choosing a CAR for Relapsed/Refractory Large B-cell LymphomaJeremy S Abramson
Pageof 20